Entera Bio Statistics
Total Valuation
Entera Bio has a market cap or net worth of $97.65 million. The enterprise value is $85.30 million.
Important Dates
The last earnings date was Friday, May 9, 2025, after market close.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Entera Bio has 45.42 million shares outstanding. The number of shares has increased by 26.85% in one year.
| Current Share Class | 45.42M |
| Shares Outstanding | 45.42M |
| Shares Change (YoY) | +26.85% |
| Shares Change (QoQ) | +10.91% |
| Owned by Insiders (%) | 1.92% |
| Owned by Institutions (%) | 3.61% |
| Float | 22.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 437.91 |
| Forward PS | n/a |
| PB Ratio | 5.04 |
| P/TBV Ratio | 5.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 382.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.07, with a Debt / Equity ratio of 0.01.
| Current Ratio | 13.07 |
| Quick Ratio | 7.82 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -205.84 |
Financial Efficiency
Return on equity (ROE) is -71.46% and return on invested capital (ROIC) is -43.72%.
| Return on Equity (ROE) | -71.46% |
| Return on Assets (ROA) | -39.60% |
| Return on Invested Capital (ROIC) | -43.72% |
| Return on Capital Employed (ROCE) | -50.49% |
| Revenue Per Employee | $11,150 |
| Profits Per Employee | -$504,550 |
| Employee Count | 20 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Entera Bio has paid $14,000 in taxes.
| Income Tax | 14,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.60% in the last 52 weeks. The beta is 1.51, so Entera Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.51 |
| 52-Week Price Change | -12.60% |
| 50-Day Moving Average | 1.94 |
| 200-Day Moving Average | 1.95 |
| Relative Strength Index (RSI) | 54.35 |
| Average Volume (20 Days) | 42,821 |
Short Selling Information
| Short Interest | 140,530 |
| Short Previous Month | 73,121 |
| Short % of Shares Out | 0.31% |
| Short % of Float | 0.63% |
| Short Ratio (days to cover) | 3.08 |
Income Statement
In the last 12 months, Entera Bio had revenue of $223,000 and -$10.09 million in losses. Loss per share was -$0.26.
| Revenue | 223,000 |
| Gross Profit | 9,000 |
| Operating Income | -10.09M |
| Pretax Income | -8.51M |
| Net Income | -10.09M |
| EBITDA | -10.05M |
| EBIT | -10.09M |
| Loss Per Share | -$0.26 |
Full Income StatementBalance Sheet
The company has $12.57 million in cash and $220,000 in debt, giving a net cash position of $12.35 million or $0.27 per share.
| Cash & Cash Equivalents | 12.57M |
| Total Debt | 220,000 |
| Net Cash | 12.35M |
| Net Cash Per Share | $0.27 |
| Equity (Book Value) | 19.38M |
| Book Value Per Share | 0.43 |
| Working Capital | 19.60M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.36 million and capital expenditures -$11,000, giving a free cash flow of -$6.37 million.
| Operating Cash Flow | -6.36M |
| Capital Expenditures | -11,000 |
| Free Cash Flow | -6.37M |
| FCF Per Share | -$0.14 |
Full Cash Flow StatementMargins
| Gross Margin | 4.04% |
| Operating Margin | -4,522.87% |
| Pretax Margin | -4,518.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |